Diagnostik bei chronisch entzündlichen Darmerkrankungen

Zusammenfassung

Trotz zahlreicher neuer diagnostischer Möglichkeiten wie beispielsweise dem MR-Enteroklysma oder der Kapselendoskopie stellen die gezielte Anamnese mit körperlicher Untersuchung sowie die Endoskopie mit makroskopischer und histologischer Beurteilung des Kolons und des terminalen Ileums nach wie vor die Grundpfeiler in der Erstdiagnose und Differenzialdiagnose chronisch entzündlicher Darmerkrankungen dar. Ein vollständiges Bild kann analog eines Puzzles nur aus den Ergebnissen der bildgebenden Verfahren sowie der Endoskopie und eventuell komplementär mit Hilfe einer gezielten Labor- bzw. mikrobiologischen Diagnostik zusammengesetzt werden. In der Anwendung des diagnostischen Armentariums sollte, um unnötige Untersuchungen zu vermeiden, immer zwischen Primärdiagnostik bei dem V. a. eine chronisch entzündliche Darmerkrankung und bei Sicherung der Diagnose dem „Staging” der Erkrankung, sowie der Verlaufsbeurteilung bei gesichertem M. Crohn oder gesicherter Colitis ulcerosa unterschieden werden.

Abstract

Despite numerous new diagnostic tools such as capsule endoscopy or MR-enteroclysis a careful patient history, a clinical examination and an ileocolonoscopy with macroscopical and histological evaluation represent still the foundation of the diagnosis and differential diagnosis of inflammatory bowel disease. Similar to a puzzle a complete picture of the disease can only be obtained, if the results of the radiological procedures, of the endoscopy and sometimes the complementary laboratory and/or microbiological analyses are put together. However, when choosing a diagnostic procedure or strategy in the daily clinical life, one should always distinguish between the primary diagnosis of inflammatory bowel disease and the staging of established Crohn's disease or ulcerative colitis.

Chronisch entzündliche Darmerkrankung - Morbus Crohn - Colitis ulcerosa - Diagnostik

Inflammatory bowel disease - Crohn's disease - ulcerative colitis - diagnosis

Literatur

• 1 Gross V, Herfarth H. Rationaler Einsatz der diagnostischen Verfahren bei chronisch entzündlichen Darmerkrankungen.  Chir Gastroenterol. 2002;  18 308-313
• 2 Shanahan F. Antibody ‘markers’ in Crohn's disease: opportunity or overstatement?.  Gut. 1997;  40 557-558
• 3 Mow W S, Vasiliauskas E A, Lin Y C, Fleshner P R, Papadakis K A, Taylor K D, Landers C J, Abreu-Martin M T, Rotter J I, Yang H, Targan S R. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease.  Gastroenterology. 2004;  126 414-424
• 4 Conrad K, Schmechta H, Klafki A, Lobeck G, Uhlig H U, Gerdi S, Henker J. Serological differentiation of inflammatory bowel disease.  Eur J Gastroenterol Hepatol. 2002;  14 129-135
• 5 Roozendaal C, Kallenberg C G. Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)?.  Clin Exp Immunol. 1999;  116 206-213
• 6 Vasiliauskas E A, Kam L Y, Karp L C, Gaiennie J, Yang H, Targan S R. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics.  Gut. 2000;  47 487-496
• 7 Sutton C L, Yang H, Li Z, Rotter J I, Targan S R, Braun J. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease.  Gut. 2000;  46 58-63
• 8 Vermeire S, Peeters M, Vlietinck R, Joossens S, Den Hond E, Bulteel V, Bossuyt X, Geypens B, Rutgeerts P. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families.  Inflamm Bowel Dis. 2001;  7 8-15
• 9 Quinton J F, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B, Charrier G, Targan S R, Colombel J F, Poulain D. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role.  Gut. 1998;  42 788-791
• 10 Ruemmele F M, Targan S R, Levy G, Dubinsky M, Braun J, Seidman E G. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease.  Gastroenterology. 1998;  115 822-289
• 11 Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease.  Am J Gastroenterol. 2001;  96 730-734
• 12 Vermeire S, Joossens S, Peeters M, Monsuur F, Marien G, Bossuyt X, Groenen P, Vlietinck R, Rutgeerts P. Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease.  Gastroenterology. 2001;  120 827-833
• 13 Teml A, Kratzer V, Schneider B, Lochs H, Norman G L, Gangl A, Vogelsang H, Reinisch W. Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment.  Am J Gastroenterol. 2003;  98 2226-2231
• 14 Klebl F H, Bataille F, Bertea C R, Herfarth H, Hofstadter F, Scholmerich J, Rogler G. Association of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies with Vienna classification subtypes of Crohn's disease.  Inflamm Bowel Dis. 2003;  9 302-307
• 15 Klebl F H, Bataille F, Hofstadter F, Herfarth H, Scholmerich J, Rogler G, Bertea C R. Optimising the diagnostic value of Anti-Saccharomyces cerevisiae-antibodies (ASCA) in Crohn's disease. Association of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies with Vienna classification subtypes of Crohn's disease.  Int J Colorectal Dis. 2004;  9 319-324
• 16 Sandborn W J, Loftus E V, Colombel J F, Fleming K A, Seibold F, Homburger H A, Sendid B, Chapman R W, Tremaine W J, Kaul D K, Wallace J, Harmsen W S, Zinsmeister A R, Targan S R. Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease.  Inflamm Bowel Dis. 2001;  7 192-201
• 17 Geboes K, De Hertogh G. Indeterminate colitis.  Inflamm Bowel Dis. 2003;  9 324-331
• 18 Joossens S, Reinisch W, Vermeire S, Sendid B, Poulain D, Peeters M, Geboes K, Bossuyt X, Vandewalle P, Oberhuber G, Vogelsang H, Rutgeerts P, Colombel J F. The value of serologic markers in indeterminate colitis: a prospective follow-up study.  Gastroenterology. 2002;  122 1242-1247
• 19 Dubinsky M C, Ofman J J, Urman M, Targan S R, Seidman E G. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease.  Am J Gastroenterol. 2001;  96 758-765
• 20 Ahmad T, Satsangi J, McGovern D, Bunce M, Jewell D P. The genetics of inflammatory bowel disease.  Aliment Pharmacol Ther. 2001;  15 731-748
• 21 Ogura Y, Bonen D K, Inohara N, Nicolae D L, Chen F F, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr R H, Achkar J P, Brant S R, Bayless T M, Kirschner B S, Hanauer S B, Nunez G, Cho J H. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease.  Nature. 2001;  411 603-606
• 22 Hampe J, Cuthbert A, Croucher P J, Mirza M M, Mascheretti S, Fisher S, Frenzel H, King K, Hasselmeyer A, MacPherson A J, Bridger S, van Deventer S, Forbes A, Nikolaus S, Lennard-Jones J E, Foelsch U R, Krawczak M, Lewis C, Schreiber S, Mathew C G. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations.  Lancet. 2001;  357 1925-1928
• 23 Hugot J P, Chamaillard M, Zouali H, Lesage S, Cezard J P, Belaiche J, Almer S, Tysk C, O'Morain C A, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel J F, Sahbatou M, Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease.  Nature. 2001;  411 599-603
• 24 Inoue N, Tamura K, Kinouchi Y, Fukuda Y, Takahashi S, Ogura Y, Inohara N, Nunez G, Kishi Y, Koike Y, Shimosegawa T, Shimoyama T, Hibi T. Lack of common NOD2 variants in Japanese patients with Crohn's disease.  Gastroenterology. 2002;  123 86-91
• 25 Leong R W, Armuzzi A, Ahmad T, Wong M L, Tse P, Jewell D P, Sung J J. NOD2/CARD15 gene polymorphisms and Crohn's disease in the Chinese population.  Aliment Pharmacol Ther. 2003;  17 1465-1470
• 26 Esters N, Pierik M, van Steen K, Vermeire S, Claessens G, Joossens S, Vlietinck R, Rutgeerts P. Transmission of CARD15 (NOD2) variants within families of patients with inflammatory bowel disease.  Am J Gastroenterol. 2004;  99 299-305
• 27 Vermeire S, Wild G, Kocher K, Cousineau J, Dufresne L, Bitton A, Langelier D, Pare P, Lapointe G, Cohen A, Daly M J, Rioux J D. CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure.  Am J Hum Genet. 2002;  71 74-83
• 28 Rosenstiel P, Fantini M, Brautigam K, Kuhbacher T, Waetzig G H, Seegert D, Schreiber S. TNF-alpha and IFN-gamma regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells.  Gastroenterology. 2003;  124 1001-1009
• 29 Ogura Y, Lala S, Xin W, Smith E, Dowds T A, Chen F F, Zimmermann E, Tretiakova M, Cho J H, Hart J, Greenson J K, Keshav S, Nunez G. Expression of NOD2 in Paneth cells: a possible link to Crohn's ileitis.  Gut. 2003;  52 1591-1597
• 30 Hisamatsu T, Suzuki M, Reinecker H C, Nadeau W J, McCormick B A, Podolsky D K. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells.  Gastroenterology. 2003;  124 993-1000
• 31 Lesage S, Zouali H, Cezard J P, Colombel J F, Belaiche J, Almer S, Tysk C, O'Morain C, Gassull M, Binder V, Finkel Y, Modigliani R, Gower-Rousseau C, Macry J, Merlin F, Chamaillard M, Jannot A S, Thomas G, Hugot J P. CARD15/NOD2 Mutational Analysis and Genotype-Phenotype Correlation in 612 Patients with Inflammatory Bowel Disease.  Am J Hum Genet. 2002;  70 845-857
• 32 Cuthbert A, Fisher S, Mirza M, King K, Hampe J, Croucher P, Mascheretti S, Sanderson J, Forbes A, Mansfield J, Schreiber S, Lewis C, Mathew C. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease.  Gastroenterology. 2002;  122 867-874
• 33 Ahmad T, Armuzzi A, Bunce M, Mulcahy-Hawes K, Marshall S, Orchard T, Crawshaw J, Large O, De Silva A, Cook J, Barnardo M, Cullen S, Welsh K, Jewell D. The molecular classification of the clinical manifestations of Crohn's disease.  Gastroenterology. 2002;  122 854-866
• 34 Vermeire S, Louis E, Rutgeerts P, De Vos M, Van Gossum A, Belaiche J, Pescatore P, Fiasse R, Pelckmans P, Vlietinck R, Merlin F, Zouali H, Thomas G, Colombel J F, Hugot J P. NOD2/CARD15 does not influence response to infliximab in Crohn's disease.  Gastroenterology. 2002;  123 106-111
• 35 Brant S R, Picco M F, Achkar J P, Bayless T M, Kane S V, Brzezinski A, Nouvet F J, Bonen D, Karban A, Dassopoulos T, Karaliukas R, Beaty T H, Hanauer S B, Duerr R H, Cho J H. Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes.  Inflamm Bowel Dis. 2003;  9 281-289
• 36 Wada Y, Matsui T, Matake H, Sakurai T, Yamamoto J, Kikuchi Y, Yorioka M, Tsuda S, Yao T, Yao S, Haraoka S, Iwashita A. Intractable ulcerative colitis caused by cytomegalovirus infection: a prospective study on prevalence, diagnosis, and treatment.  Dis Colon Rectum. 2003;  46 S 59-S 65
• 37 Adani G L, Avital I, Ferraresso C, Aoki T, Papadakis K A, Tung J K, Binder S W, Kam L Y, Abreu M T, Targan S R, Vasiliauskas E A. CMV infection in severe refractory ulcerative and Crohn's colitis. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease.  Am J Gastroenterol. 2001;  96 3464-3465
• 38 Papadakis K A, Tung J K, Binder S W, Kam L Y, Abreu M T, Targan S R, Vasiliauskas E A. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease.  Am J Gastroenterol. 2001;  96 2137-2142
• 39 Michel D, Marre E, Hampl W, Roczkos J, Muller S, Hertenstein B, Kern P, Heymer B, Salzberger B, Arasteh K. et al . Intestinal cytomegalovirus disease in immunocompromised patients may be ruled out by search for cytomegalovirus DNA in stool samples.  J Clin Microbiol. 1995;  33 3064-3067
• 40 Kayazawa M, Saitoh O, Kojima K, Nakagawa K, Tanaka S, Tabata K, Matsuse R, Uchida K, Hoshimoto M, Hirata I, Katsu K. Lactoferrin in whole gut lavage fluid as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins.  Am J Gastroenterol. 2002;  97 360-369
• 41 Roseth A G, Schmidt P N, Fagerhol M K. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease.  Scand J Gastroenterol. 1999;  34 50-54
• 42 Tibble J A, Sigthorsson G, Bridger S, Fagerhol M K, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease.  Gastroenterology. 2000;  119 15-22
• 43 Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, Foster R, Sherwood R, Fagerhol M, Bjarnason I. A simple method for assessing intestinal inflammation in Crohn's disease.  Gut. 2000;  47 506-513
• 44 Kane S V, Sandborn W J, Rufo P A, Zholudev A, Boone J, Lyerly D, Camilleri M, Hanauer S B. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation.  Am J Gastroenterol. 2003;  98 1309-1314
• 45 Carroccio A, Iacono G, Cottone M, Di Prima L, Cartabellotta F, Cavataio F, Scalici C, Montalto G, Di Fede G, Rini G, Notarbartolo A, Averna M R. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children.  Clin Chem. 2003;  49 861-867
• 46 Carroll D, Corfield A, Spicer R, Cairns P. Faecal calprotectin concentrations and diagnosis of necrotising enterocolitis.  Lancet. 2003;  361 310-311
• 47 Olafsdottir E, Aksnes L, Fluge G, Berstad A. Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children.  Acta Paediatr. 2002;  91 45-50
• 48 Summerton C B, Longlands M G, Wiener K, Shreeve D R. Faecal calprotectin: a marker of inflammation throughout the intestinal tract.  Eur J Gastroenterol Hepatol. 2002;  14 841-845
• 49 Hirche T O, Russler J, Schroder O, Schuessler G, Kappeser P, Caspary W F, Dietrich C F. The value of routinely performed ultrasonography in patients with Crohn's disease.  Scand J Gastroenterol. 2002;  37 1178-1183
• 50 Sheridan M B, Nicholson D A, Martin D F. Transabdominal ultrasonography as the primary investigation in patients with suspected Crohn's disease or recurrence: a prospective study.  Clin Radiol. 1993;  48 402-404
• 51 Hollerbach S, Geissler A, Schiegl H, Kullmann F, Lock G, Schmidt J, Schlegel J, Schoelmerich J, Andus T. The accuracy of abdominal ultrasound in the assessment of bowel disorders.  Scand J Gastroenterol. 1998;  33 1201-1208
• 52 Parente F, Greco S, Molteni M, Cucino C, Maconi G, Sampietro G M, Danelli P G, Cristaldi M, Bianco R, Gallus S, Bianchi Porro G. Role of early ultrasound in detecting inflammatory intestinal disorders and identifying their anatomical location within the bowel.  Aliment Pharmacol Ther. 2003;  18 1009-1016
• 53 Haber H P, Busch A, Ziebach R, Dette S, Ruck P, Stern M. Ultrasonographic findings correspond to clinical, endoscopic, and histologic findings in inflammatory bowel disease and other enterocolitides.  J Ultrasound Med. 2002;  21 375-382
• 54 Limberg B. Hydrocolonic sonography-potentials and limitations of ultrasonographic diagnosis of colon diseases.  Z Gastroenterol. 2001;  39 1007-1015
• 55 Bru C, Sans M, Defelitto M M, Gilabert R, Fuster D, Llach J, Lomena F, Bordas J M, Pique J M, Panes J. Hydrocolonic sonography for evaluating inflammatory bowel disease.  AJR Am J Roentgenol. 2001;  177 99-105
• 56 Maconi G, Parente F, Bollani S, Cesana B, Bianchi Porro G. Abdominal ultrasound in the assessment of extent and activity of Crohn's disease: clinical significance and implication of bowel wall thickening.  Am J Gastroenterol. 1996;  91 1604-1609
• 57 Mayer D, Reinshagen M, Mason R A, Muche R, von Tirpitz C, Eckelt D, Adler G, Beckh K, Kratzer W. Sonographic measurement of thickened bowel wall segments as a quantitative parameter for activity in inflammatory bowel disease.  Z Gastroenterol. 2000;  38 295-300
• 58 Gasche C, Moser G, Turetschek K, Schober E, Moeschl P, Oberhuber G. Transabdominal bowel sonography for the detection of intestinal complications in Crohn's disease.  Gut. 1999;  44 112-117
• 59 Parente F, Maconi G, Bollani S, Anderloni A, Sampietro G, Cristaldi M, Franceschelli N, Bianco R, Taschieri A M, Bianchi Porro G. Bowel ultrasound in assessment of Crohn's disease and detection of related small bowel strictures: a prospective comparative study versus X-ray and intraoperative findings.  Gut. 2002;  50 490-495
• 60 Maconi G, Bollani S, Bianchi Porro G. Ultrasonographic detection of intestinal complications in Crohn's disease.  Dig Dis Sci. 1996;  41 1643-1648
• 61 Potthast S, Rieber A, Von Tirpitz C, Wruk D, Adler G, Brambs H J. Ultrasound and magnetic resonance imaging in Crohn's disease: a comparison.  Eur Radiol. 2002;  12 1416-1422
• 62 van Oostayen J A, Wasser M N, van Hogezand R A, Griffioen G, Biemond I, Lamers C B, de Roos A. Doppler sonography evaluation of superior mesenteric artery flow to assess Crohn's disease activity: correlation with clinical evaluation, Crohn's disease activity index, and alpha 1-antitrypsin clearance in feces.  AJR Am J Roentgenol. 1997;  168 429-433
• 63 van Oostayen J A, Wasser M N, Griffioen G, van Hogezand R A, Lamers C B, de Roos A. Diagnosis of Crohn's ileitis and monitoring of disease activity: value of Doppler ultrasound of superior mesenteric artery flow.  Am J Gastroenterol. 1998;  93 88-91
• 64 Ludwig D, Wiener S, Bruning A, Schwarting K, Jantschek G, Fellermann K, Stahl M, Stange E F. Mesenteric blood flow is related to disease activity and risk of relapse in ulcerative colitis: a prospective follow up study.  Gut. 1999;  45 546-552
• 65 Ludwig D, Wiener S, Bruning A, Schwarting K, Jantschek G, Stange E F. Mesenteric blood flow is related to disease activity and risk of relapse in Crohn's disease: a prospective follow-up study.  Am J Gastroenterol. 1999;  94 2942-2950
• 66 Sellink J L. Radiologic examination of the small intestine by duodenal intubation.  Acta Radiol Diagn (Stockh). 1974;  15 318-332
• 67 Feuerbach S, Schölmerich J. Chronisch entzündliche Darmerkrankungen: Morbus Crohn und Colitis ulcerosa.  Radiologe. 2000;  40 324-338
• 68 Schreyer A, Seitz J, Feuerbach S, Rogler G, Herfarth H. Modern imaging using Computer Tomography and Magnetic Resonance Imaging for inflammatory bowel disease (IBD).  Inflamm Bowel Dis. 2004;  10 45-54
• 69 Rieber A, Wruk D, Potthast S, Nussle K, Reinshagen M, Adler G, Brambs H J. Diagnostic imaging in Crohn's disease: comparison of magnetic resonance imaging and conventional imaging methods.  Int J Colorectal Dis. 2000;  15 176-181
• 70 Schreyer A G, Golder S, Seitz J, Herfarth H. New diagnostic avenues in inflammatory bowel diseases. Capsule endoscopy, magnetic resonance imaging and virtual enteroscopy.  Dig Dis. 2003;  21 129-137
• 71 Wold P B, Fletcher J G, Johnson C D, Sandborn W J. Assessment of Small Bowel Crohn Disease: Noninvasive Peroral CT Enterography Compared with Other Imaging Methods and Endoscopy - Feasibility Study.  Radiology. 2003;  229 275-281
• 72 Strotzer M, Manke C, Lock G, Bregenzer N, Schölmerich J, Feuerbach S. Perkutane Abszessdrainage bei Patienten mit Morbus Crohn.  Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr. 1998;  169 510-514
• 73 Gervais D A, Hahn P F, O'Neill M J, Mueller P R. Percutaneous abscess drainage in Crohn's disease: technical success and short- and long-term outcomes during 14 years.  Radiology. 2002;  222 645-651
• 74 Schreyer A G, Herfarth H, Kikinis R, Seitz J, Scholmerich J, Geissler A, Feuerbach S. 3D modeling and virtual endoscopy of the small bowel based on magnetic resonance imaging in patients with inflammatory bowel disease.  Invest Radiol. 2002;  37 528-533
• 75 Dejaco C, Oesterreicher C, Angelberger S, Puspok A, Birner P, Poetzi R, Gangl A, Oberhuber G. Diagnosing colitis: a prospective study on essential parameters for reaching a diagnosis.  Endoscopy. 2003;  35 1004-1008
• 76 Modigliani R, Mary J Y, Simon J F, Cortot A, Soule J C, Gendre J P, Rene E. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives.  Gastroenterology. 1990;  98 811-818
• 77 Schmiegel W, Adler G, Fruhmorgen P, Folsch U, Graeven U, Layer P, Petrasch S, Porschen R, Pox C, Sauerbruch T, Schmoll H J, Zeitz M. Prävention und Früherkennung in der asymptomatischen Bevölkerung - Vorsorge bei Risikogruppen - Endoskopische Diagnostik und Therapie von Polypen und Karzinomen.  Z Gastroenterol. 2000;  38 49-75
• 78 Bernstein C N, Blanchard J F, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study.  Cancer. 2001;  91 854-862
• 79 Ekbom A, Helmick C, Zack M, Adami H O. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement.  Lancet. 1990;  336 357-359
• 80 Friedman S, Rubin P H, Bodian C, Goldstein E, Harpaz N, Present D H. Screening and surveillance colonoscopy in chronic Crohn's colitis.  Gastroenterology. 2001;  120 820-826
• 81 Herfarth H. Karzinomrisiko und Prävention bei chronisch entzündlichen Darmerkrankungen.  Chirurgische Gastroenterologie. 2002;  18 319-324
• 82 Kiesslich R, Neurath M F. Surveillance colonoscopy in ulcerative colitis: magnifying chromoendoscopy in the spotlight.  Gut. 2004;  53 165-167
• 83 Messmann H. Fluoreszenzendoskopie in der Gastroenterologie.  Z Gastroenterol. 2000;  38 21-30
• 84 Endlicher E, Herfarth H, Messmann H, Schölmerich J. Strategische Konzepte bei Diagnostik und Therapie von Dysplasien bei chronisch entzündlichen Darmerkrankungen.  Chir Gastroenterol. 2002;  18 148-154
• 85 Rutter M D, Saunders B P, Schofield G, Forbes A, Price A B, Talbot I C. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis.  Gut. 2004;  53 256-260
• 86 Kiesslich R, Fritsch J, Holtmann M, Koehler H H, Stolte M, Kanzler S, Nafe B, Jung M, Galle P R, Neurath M F. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis.  Gastroenterology. 2003;  124 880-888
• 87 Messmann H, Endlicher E, Freunek G, Rummele P, Scholmerich J, Knuchel R. Fluorescence endoscopy for the detection of low and high grade dysplasia in ulcerative colitis using systemic or local 5-aminolaevulinic acid sensitisation.  Gut. 2003;  52 1003-1007
• 88 Meining A, Rosch T, Kiesslich R, Muders M, Sax F, Heldwein W. Inter- and intra-observer variability of magnification chromoendoscopy for detecting specialized intestinal metaplasia at the gastroesophageal junction.  Endoscopy. 2004;  36 160-164
• 89 Herfarth H, Schreyer A G. The virtuosity of virtuality or how real is virtual colonography.  Gut. 2003;  52 1662-1664
• 90 Biancone L, Fiori F, Tosti S, Marinetti A, Catarinacci M, De Nigris F, Simonetti G, Pallone F. Virtual colonoscopy compared with conventional colonoscopy for stricturing postoperative recurrence in Crohn's disease.  Inflamm Bowel Dis. 2003;  9 343-350
• 91 Schreyer A G, Rath H C, Kikinis R, Völk M, Schölmerich J, Feuerbach S, Rogler G, Seitz J, Herfarth H. A comparison of MRI colonography with conventional colonoscopy for the assessment of intestinal inflammation in patients with inflammatory bowel disease.  Gut. 2004;  in press
• 92 Eliakim R, Fischer D, Suissa A, Yassin K, Katz D, Guttman N, Migdal M. Wireless capsule video endoscopy is a superior diagnostic tool in comparison to barium follow-through and computerized tomography in patients with suspected Crohn's disease.  Eur J Gastroenterol Hepatol. 2003;  15 363-367
• 93 Fireman Z, Mahajna E, Broide E, Shapiro M, Fich L, Sternberg A, Kopelman Y, Scapa E. Diagnosing small bowel Crohn's disease with wireless capsule endoscopy.  Gut. 2003;  52 390-392
• 94 Mow W S, Lo S K, Targan S R, Dubinsky M C, Treyzon L, Abreu-Martin M T, Papadakis K A, Vasiliauskas E A, Voderholzer W A, Ortner M, Rogalla P, Beinholzl J, Lochs H. Initial experience with wireless capsule enteroscopy in the diagnosis and management of inflammatory bowel disease. Diagnostic yield of wireless capsule enteroscopy in comparison with computed tomography enteroclysis.  Clin Gastroenterol Hepatol. 2004;  2 31-40
• 95 Voderholzer W A, Ortner M, Rogalla P, Beinholzl J, Lochs H. Diagnostic yield of wireless capsule enteroscopy in comparison with computed tomography enteroclysis.  Endoscopy. 2003;  35 1009-1014
• 96 Rösch T, Ell C. Derzeitige Bewertung der Kapselendoskopie in der Diagnostik von Dünndarmerkrankungen.  Z Gastroenterol. 2004;  42 247-259
• 97 Schumacher G, Sandstedt B, Mollby R, Kollberg B. Clinical and histologic features differentiating non-relapsing colitis from first attacks of inflammatory bowel disease.  Scand J Gastroenterol. 1991;  26 151-161
• 98 Parsi M A, Shen B, Achkar J P, Remzi F, Goldblum J R, Boone J, Lin D, Connor J T, Fazio V W, Lashner B A. Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis.  Gastroenterology. 2004;  in press
• 99 Holzknecht N, Helmberger T, von Ritter C, Gauger J, Faber S, Reiser M. MRI of the small intestine with rapid MRI sequences in Crohn disease after enteroclysis with oral iron particles.  Radiologe. 1998;  38 29-36
• 100 Schunk K, Kern A, Heussel C P, Kalden P, Orth T, Wanitschke R, Thelen M. Hydro-MRT with fast sequences in Crohn's disease: a comparison with fractionated gastrointestinal passage.  Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr. 1999;  170 338-346
• 101 Aschoff A J, Zeitler H, Merkle E M, Reinshagen M, Brambs H J, Rieber A. MR enteroclysis for nuclear spin tomographic diagnosis of inflammatory bowel diseases with contrast enhancement.  Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr. 1997;  167 387-391
• 102 Rieber A, Wruk D, Nussle K, Aschoff A J, Reinshagen M, Adler G, Brambs H J, Tomczak R. MRI of the abdomen combined with enteroclysis in Crohn's disease using oral and intravenous Gd-DTPA.  Radiologe. 1998;  38 23-28
• 103 Schreyer A G, Geissler A, Albrich H, Schölmerich J, Feuerbach S, Rogler G, Völk M, Herfarth H. Abdominal MRI after enteroclysis or with oral contrast in patients with suspected or proven Crohn's disease.  Clin Gastroenterol Hepatol. 2004;  2 491-497
• 104 Modigliani R, Mary J Y, Simon J F, Cortot A, Soule J C, Gendre J P, Rene E. Endoscopic severity index for Crohn's disease. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives.  Gastrointest Endosc. 1990;  36 637